- Home
- SEZL vs DYN Comparison
SEZL vs DYN Comparison
Compare SEZL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEZL | DYN |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SEZL | DYN |
|---|---|---|
| Price | $60.80 | $17.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $114.20 | $37.00 |
| AVG Volume (30 Days) | 530.8K | ★ 2.4M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $450,279,000.00 | N/A |
| Revenue This Year | $30.03 | N/A |
| Revenue Next Year | $24.41 | N/A |
| P/E Ratio | $16.56 | ★ N/A |
| Revenue Growth | ★ 66.08 | N/A |
| 52 Week Low | $25.00 | $7.01 |
| 52 Week High | $186.74 | $25.00 |
Technical Indicators
Market Signals| Indicator | SEZL | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 47.54 |
| Support Level | $56.42 | $16.34 |
| Resistance Level | $70.80 | $19.77 |
| Average True Range (ATR) | 4.48 | 1.14 |
| MACD | -0.91 | -0.07 |
| Stochastic Oscillator | 5.66 | 6.41 |
Price Performance
Historical ComparisonAbout SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.